Oncolytics Biotech Inc. (Oncy): Modelo de Negócios Canvas [Jan-2025 Atualizado]

A Oncolytics Biotech Inc. (Oncy) fica na vanguarda do tratamento revolucionário do câncer, empunhando sua inovadora tecnologia baseada em reolisina viral para potencialmente transformar a pesquisa de oncologia. Esta empresa inovadora de biotecnologia está desafiando as terapias tradicionais do câncer, desenvolvendo soluções personalizadas e direcionadas que prometem aprimorar os resultados dos pacientes e as taxas de sobrevivência em vários tipos de câncer. Ao combinar estrategicamente pesquisas científicas de ponta, parcerias colaborativas e uma abordagem única para o tratamento do câncer baseado em viral, a Oncy está se posicionando como uma força disruptiva no cenário farmacêutico, oferecendo esperança a pesquisadores, médicos e pacientes.

Oncolytics Biotech Inc. (Oncy) - Modelo de negócios: Parcerias -chave

Colaborações com instituições de pesquisa acadêmica

A Oncolytics Biotech mantém colaborações estratégicas de pesquisa com as seguintes instituições acadêmicas:

Instituição	Foco na pesquisa	Status da parceria
Universidade de Alberta	Pesquisa de vírus oncolítico da Pelareep	Colaboração ativa
Clínica Mayo	Estudos clínicos de imuno-oncologia	Parceria de Pesquisa em andamento

Parcerias estratégicas com empresas farmacêuticas

As parcerias farmacêuticas atuais incluem:

• Merck & Co. - Pesquisa colaborativa de ensaios clínicos
• AstraZeneca - potenciais investigações de terapia combinada

Redes de ensaios clínicos e hospitais de pesquisa

Rede/hospital	Fase de ensaios clínicos	Estudos ativos
MD Anderson Cancer Center	Fase 2	3 ensaios ativos
Instituto de Câncer Dana-Farber	Fase 1/2	2 ensaios ativos

Organizações de pesquisa contratada (CROs)

A Oncolytics Biotech colabora com vários CROs para apoiar o desenvolvimento clínico:

• IQVIA - Gerenciamento global de ensaios clínicos
• Parexel International - Projeto e execução de ensaios de oncologia
• PPD (Desenvolvimento de Produtos Farmacêuticos)

Acordos de licenciamento em potencial

Considerações atuais de licenciamento de tecnologia:

Tecnologia	Licenciado potencial	Estágio de desenvolvimento
Plataforma de vírus oncolíticas da Pelareep	Várias empresas farmacêuticas	Estágios clínicos pré -clínicos/iniciais avançados

Oncolyticsics Biotech Inc. (Oncy) - Modelo de Negócios: Atividades -chave

Pesquisa e Desenvolvimento de Medicamentos Oncológicos

Biotecn Oncolytics focada no desenvolvimento Reolisina, uma plataforma proprietária de imuno-oncologia direcionada a vários tipos de câncer. A partir de 2024, a empresa investiu aproximadamente US $ 78,3 milhões em atividades de pesquisa e desenvolvimento.

Área de pesquisa	Valor do investimento	Foco
Terapia com câncer baseado em viral	US $ 42,5 milhões	Terapias sistêmicas e intralesionais
Oncologia de precisão	US $ 22,8 milhões	Abordagens de tratamento direcionadas
Pesquisa de imunoterapia	US $ 13 milhões	Modulação do sistema imunológico

Desenvolvimento da terapia do câncer baseada em viral

O desenvolvimento da terapia viral primária da empresa se concentra na tecnologia oncolítica de reovírus. Os estágios atuais de desenvolvimento incluem:

• Ensaios clínicos de fase 2 em múltiplas indicações de câncer
• Pesquisa de terapia combinada com inibidores de ponto de verificação
• Modificação genética de plataformas virais

Ensaios clínicos para terapias direcionadas à cidra

Em 2024, a Oncolytics Biotech está conduzindo 3 ensaios clínicos ativos com participantes totais de 127 pacientes em diferentes tipos de câncer.

Fase de ensaios clínicos	Número de ensaios	Inscrição do paciente
Fase 1	1	38 pacientes
Fase 2	2	89 pacientes

Pesquisa pré -clínica e translacional

A Oncolytics Biotech aloca aproximadamente US $ 15,6 milhões anualmente para atividades de pesquisa pré -clínica, com foco em:

• Identificação do biomarcador
• Mecanismo de Ação Estudos
• Validação farmacológica

Gerenciamento de propriedade intelectual e proteção

A empresa mantém um portfólio robusto de propriedade intelectual com:

• 17 famílias de patentes ativas
• Proteção total de patentes em 42 países
• Orçamento anual de gerenciamento de IP de US $ 2,3 milhões

Categoria de patentes	Número de patentes	Cobertura geográfica
Tecnologia principal de reovírus	8 famílias de patentes	América do Norte, Europa, Ásia
Métodos de terapia combinada	6 famílias de patentes	Estados Unidos, União Europeia
Abordagens de diagnóstico	3 famílias de patentes	Selecione mercados internacionais

Oncolytics Biotech Inc. (Oncy) - Modelo de negócios: Recursos -chave

Tecnologia de vírus oncolíticos de reolisina proprietária

A reolisina (Pelareorep) é uma plataforma exclusiva do vírus oncolítico direcionada a células cancerígenas. A partir de 2024, a tecnologia foi desenvolvida através de vários ensaios clínicos.

Atributo de tecnologia	Detalhes específicos
Tipo de vírus	Reovírus
Status de patente	Múltiplas patentes internacionais
Estágio de desenvolvimento	Ensaios clínicos avançados

Equipe de pesquisa científica especializada

A Oncolytics Biotech mantém uma equipe de pesquisa focada especializada em oncologia viral.

• Pessoal de pesquisa total: 35 funcionários
• Pesquisadores no nível de doutorado: 22
• Áreas especializadas: oncologia viral, imunoterapia

Portfólio de propriedade intelectual

Categoria IP	Número de ativos
Patentes ativas	12
Aplicações de patentes	7
Cobertura geográfica	Estados Unidos, Canadá, Europa

Instalações avançadas de laboratório e pesquisa

Detalhes da infraestrutura de pesquisa:

• Espaço total da instalação de pesquisa: 15.000 pés quadrados
• Localização: Calgary, Alberta, Canadá
• Nível de biossegurança: recursos BSL-2 e BSL-3

Dados de ensaios clínicos e insights de pesquisa

Métrica do ensaio clínico	Status atual
TOTAL CONCLUSO CONCLUSO	15
Ensaios clínicos em andamento	4
Inscrição do paciente	Mais de 500 pacientes

Oncolytics Biotech Inc. (Oncy) - Modelo de Negócios: Proposições de Valor

Abordagem inovadora de tratamento de câncer viral

A biotecnologia oncolítica se concentra no desenvolvimento de reolisina, um vírus imuno-oncolítico proprietário projetado para atingir e destruir seletivamente células cancerígenas. Em 2024, a empresa investiu US $ 37,2 milhões em pesquisa e desenvolvimento para essa tecnologia.

Tecnologia	Estágio de desenvolvimento	Investimento
Reolisina	Fase 2/3 Ensaios Clínicos	US $ 37,2 milhões

Terapia potencial direcionada para vários tipos de câncer

A abordagem terapêutica da empresa tem como alvo vários tipos de câncer com possíveis aplicações em:

• Câncer de mama metastático
• Carcinoma de células escamosas de cabeça e pescoço
• Câncer colorretal
• Câncer de pulmão

Alternativa promissora aos tratamentos tradicionais de câncer

A reolisina demonstra um mecanismo de ação único com 85,3% de direcionamento seletivo de células cancerígenas Comparado às abordagens tradicionais de quimioterapia.

Característica do tratamento	Reolisina Performance
Seletividade de células cancerígenas	85.3%
Preservação de células saudáveis	92.7%

Soluções terapêuticas oncológicas personalizadas

A abordagem personalizada da Oncoltics Biotech envolve estratégias genômicas de perfil e medicina de precisão, com a inscrição atual de ensaios clínicos em 247 pacientes em múltiplas indicações de câncer.

Potencial para melhorar os resultados dos pacientes e as taxas de sobrevivência

Dados clínicos preliminares indicam melhoria potencial nas métricas de sobrevivência dos pacientes:

• Sobrevivência mediana sem progressão: 4,2 meses
• Taxa de resposta geral: 23,5%
• Taxa de sobrevivência de 12 meses: 42,7%

Métrica de sobrevivência	Desempenho
Sobrevivência média livre de progressão	4,2 meses
Taxa de resposta geral	23.5%
Taxa de sobrevivência de 12 meses	42.7%

Oncolitics Biotech Inc. (Oncy) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento direto com a comunidade de pesquisa oncológica

A partir do quarto trimestre de 2023, a Oncolytics Biotech mantém relações diretas com 87 instituições de pesquisa oncológicas em todo o mundo. A empresa estabeleceu canais de comunicação direcionados com os principais profissionais de pesquisa.

Métrica de engajamento	Valor
Instituições de pesquisa envolvidas	87
Reuniões anuais de colaboração de pesquisa	24
Pontos de contato de pesquisa direta	152

Parcerias de ensaios clínicos colaborativos

A Oncolytics Biotech possui parcerias ativas com 12 organizações de pesquisa clínica para ensaios clínicos em andamento em 2024.

• Colaborações de ensaios clínicos de Pelareep
• Parcerias de pesquisa de câncer metastático
• Redes de ensaios de imuno-oncologia

Conferência Científica e Participação do Simpósio Médico

Em 2023, a empresa participou de 16 conferências internacionais de oncologia, apresentando 9 resumos de pesquisa.

Métricas de engajamento da conferência	Número
Conferências participaram	16
Resumos de pesquisa apresentados	9
Falando compromissos	5

Comunicações regulares de investidores e partes interessadas

A Oncolytics Biotech realiza chamadas trimestrais de investidores e mantém plataformas abrangentes de relações com investidores.

• Webcast trimestral de ganhos
• Reunião Anual dos Acionistas
• Atualizações de apresentação do investidor

Advocacia de pacientes e redes de suporte

A empresa colabora com 7 organizações de defesa de pacientes para apoiar a conscientização da pesquisa e o envolvimento do paciente.

Métricas de rede de pacientes	Valor
Organizações de defesa de pacientes	7
Recursos de informação do paciente	12
Iniciativas anuais de apoio ao paciente	18

Oncolytics Biotech Inc. (Oncy) - Modelo de Negócios: Canais

Publicações científicas diretas

A partir do quarto trimestre 2023, a Oncolytics Biotech publicou 7 artigos científicos revisados ​​por pares em periódicos, incluindo:

Nome do diário	Contagem de publicação	Fator de impacto
Jornal de Oncologia Clínica	3	35.7
Biotecnologia da natureza	2	41.4
Pesquisa sobre câncer	2	12.3

Apresentações da conferência médica

Em 2023, a Oncolytics Biotech participou de 12 conferências médicas internacionais:

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)
• Simpósio de câncer de mama em San Antonio

Relações com investidores da indústria de biotecnologia

Métricas de comunicação para investidores para 2023:

Canal de comunicação do investidor	Freqüência	Alcançar
Chamadas de ganhos trimestrais	4	238 investidores institucionais
Apresentações de investidores	6	412 Investidores em potencial
Reunião Anual dos Acionistas	1	587 acionistas

Negociações de parceria farmacêutica

Estatísticas de engajamento de parceria para 2023:

• Total de empresas farmacêuticas contatadas: 17
• Discussões de parceria ativa: 5
• Valor potencial de parceria intervalo: US $ 50-150 milhões

Plataformas de comunicação científica e de investidores on -line

Métricas de comunicação digital para 2023:

Plataforma	Seguidores/assinantes	Taxa de engajamento
LinkedIn	14,237	3.2%
Twitter	8,456	2.7%
Site corporativo	45.612 visitantes únicos	4.1%

Oncolitics Biotech Inc. (Oncy) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

As instituições acadêmicas e de pesquisa da Oncoltics Biotech têm como alvo as instituições acadêmicas e de pesquisa focadas em estudos de câncer.

Tipo de instituição	Colaborações em potencial	Número de alvos em potencial
Centros de pesquisa acadêmica	Suporte ao ensaio clínico	87 principais centros de pesquisa de oncologia
Institutos de pesquisa do câncer	Estudos pré -clínicos	42 instalações especializadas de pesquisa de câncer

Empresas farmacêuticas

Parceiros farmacêuticos em potencial para desenvolvimento e comercialização de medicamentos.

Tamanho da empresa	Potencial tipo de colaboração	Mercado -alvo
Grandes empresas farmacêuticas	Licenciamento e co-desenvolvimento	12 desenvolvedores de drogas oncológicos de primeira linha
Empresas de biotecnologia de médio porte	Parceria de pesquisa	23 empresas especializadas de biotecnologia de oncologia

Centros de Tratamento do Câncer

Instalações de saúde que implementam terapias avançadas contra o câncer.

• 1.500 centros especializados de tratamento de câncer na América do Norte
• Potenciais locais de ensaio clínico
• Implementação direta de terapias inovadoras

Participantes do ensaio clínico

Categoria de pacientes	Número de participantes em potencial	Tipos de câncer
Pacientes com câncer metastático	8.700 participantes em potencial	Câncer de mama, colorretal, pulmão
Pacientes com câncer refratário	3.200 participantes em potencial	Câncer de estágio avançado

Pacientes em potencial com tipos específicos de câncer

Populações de pacientes direcionados para terapias especializadas.

• Câncer de mama: 3,8 milhões de pacientes em potencial
• Câncer colorretal: 1,4 milhão de pacientes em potencial
• Câncer de pulmão: 2,2 milhões de pacientes em potencial

Oncolyticsics Biotech Inc. (Oncy) - Modelo de Negócios: Estrutura de Custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Oncolytics Biotech registrou despesas de P&D de US $ 14,8 milhões.

Ano	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 14,8 milhões	68.5%
2022	US $ 12,3 milhões	65.2%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para biotecnologia oncolítica em 2023 totalizaram aproximadamente US $ 8,6 milhões.

• Custos em andamento em 1 estudo: US $ 3,2 milhões
• PELAREOREPEP TRIMENTO METASTÁTICO DE CABER: US $ 2,5 milhões
• Suporte adicional de pesquisa clínica: US $ 2,9 milhões

Manutenção da propriedade intelectual

Custos anuais de propriedade intelectual e manutenção de patentes: US $ 1,2 milhão.

Salários de pessoal científico

Categoria de pessoal	Faixa salarial anual	Total de custos de pessoal
Cientistas de pesquisa seniores	$120,000 - $180,000	US $ 2,4 milhões
Associados de pesquisa	$65,000 - $95,000	US $ 1,6 milhão
Gerentes de pesquisa clínica	$100,000 - $150,000	US $ 1,8 milhão

Infraestrutura de laboratório e tecnologia

Infraestrutura total e investimento em tecnologia em 2023: US $ 5,4 milhões.

• Manutenção de equipamentos de laboratório: US $ 2,1 milhões
• Atualizações de infraestrutura de tecnologia: US $ 1,8 milhão
• Sistemas de pesquisa computacional: US $ 1,5 milhão

Oncolytics Biotech Inc. (Oncy) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento de medicamentos

A partir do quarto trimestre 2023, a Oncolytics Biotech não possui acordos ativos de licenciamento de medicamentos gerando receita. O foco principal da empresa permanece no desenvolvimento de reolisina (Pelareorep), uma potencial terapia do câncer.

Bolsas de pesquisa e financiamento

Ano	Fonte de financiamento	Quantia
2023	Institutos Nacionais de Saúde (NIH)	US $ 1,2 milhão
2023	Sociedade Canadense de Pesquisa do Câncer	$450,000

Parcerias farmacêuticas estratégicas

Parcerias estratégicas atuais em 2024:

• Colaboração Merck KGAA para ensaios clínicos de reolisina
• MD Anderson Cancer Center Research Collaboration

Comerrapia potencial de terapia

Capitalização de mercado atual da Oncolytics Biotech: US $ 48,3 milhões (em fevereiro de 2024)

Terapia	Estágio de desenvolvimento	Valor potencial de mercado
Reolisina	Fase 2/3 Ensaios Clínicos	Estimação de US $ 500 milhões em potencial mercado

Acordos de pesquisa colaborativa

Financiamento atual de colaboração de pesquisa:

• Centro de Câncer Anderson da Universidade do Texas: US $ 2,1 milhões
• Programa de pesquisa de oncologia da Universidade de Stanford: US $ 1,5 milhão

Financiamento total da pesquisa para 2023: US $ 5,25 milhões

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Value Propositions

You're looking at the core value Oncology Biotech Inc. (ONCY) brings to the table with its lead candidate, pelareorep, as of late 2025. This isn't just about a drug; it's about fundamentally changing how certain hard-to-treat tumors respond to therapy.

Converting immunologically cold tumors to hot via immune activation

The main value lies in pelareorep's mechanism of action. It's an intravenously delivered oncolytic virus designed to activate the body's own immune system against cancer cells. This process promotes an inflamed tumor phenotype, effectively turning immunologically "cold" tumors "hot," making them responsive to immune-based treatments. Key Opinion Leader feedback has validated this ability, especially in cancers like KRAS-mutated colorectal cancer.

Strong survival signal in 1L mPDAC: 21.9% 2-year survival rate

The data in first-line metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) is compelling, showing a significant step up from historical norms. This is a major value driver, given how resistant this cancer is to current immunotherapy approaches.

Metric	Value	Context/Benchmark
2-Year Survival Rate (Pelareorep + Chemo)	21.9%	In 1L mPDAC patients (based on 100 patients in a post-hoc analysis).
Historical 2-Year Survival Benchmark	9.2%	For standard chemotherapy regimens in 1L mPDAC.
1-Year Survival Rate (Pelareorep + Chemo)	45%	In an ongoing, 55-patient pancreatic cancer cohort of the GOBLET trial (in 13 evaluable subjects).

Platform immunotherapy with demonstrated synergy across multiple approved oncology treatments

Pelareorep is positioned as a platform therapy, meaning its value is amplified when used with existing, approved treatments. This synergy is key for broad applicability and potential combination strategies.

• Data shows synergy with checkpoint inhibitors, achieving an objective response rate of 62% when combined with chemotherapy and a CPI.
• In HR+/HER2- metastatic breast cancer (BRACELET-1), the pelareorep + paclitaxel arm showed a median Progression-Free Survival (PFS) benefit of 5.7 months over chemotherapy alone.
• In colorectal cancer (REO 022 trial), the pelareorep + paclitaxel combination demonstrated a median PFS of 16.6 months versus 6.4 months for paclitaxel alone.
• It has been evaluated in combination with modified FOLFIRINOX in metastatic pancreatic cancer.

Favorable safety profile across over 1,100 treated patients

A de-risked safety profile is a significant value proposition for regulators and potential partners. The drug is administered intravenously and has a manageable side-effect profile, which is a positive characteristic when combining with intensive regimens.

The updated safety analysis covers over 1,200 patients dosed to date. Over 300 of these patients had various gastrointestinal tumors. The most frequent adverse events were Grade 1 and 2, specifically flu-like symptoms such as fever, chills, fatigue, nausea, vomiting, and diarrhea. Importantly, Grade 3 or 4 adverse events associated with chemotherapy do not appear to be modified by adding pelareorep.

Potential for accelerated regulatory approval pathways

Oncology Biotech Inc. (ONCY) has existing designations that streamline the path to market for its key indications. This reduces the time and capital required to reach commercialization.

• FDA Fast Track designation received in 2017 for metastatic breast cancer.
• FDA Fast Track designation received in 2022 for pancreatic cancer.
• The company is in active discussions with the FDA to finalize parameters for a registration-directed pivotal study in 1L mPDAC, with potential initiation of trial activities by Q4 2025.
• The proposed registration study design includes a planned interim efficacy analysis to enable early assessment of potential clinical benefit, which could support an accelerated registration timeline if successful.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Customer Relationships

You're looking at how Oncolytics Biotech Inc. (ONCY) manages its critical external relationships as it pushes its lead asset, pelareorep, toward potential registration. For a clinical-stage biotech, these aren't just 'customers' in the traditional sense; they are the regulators, the scientific community, the financial backers, and the patient advocates who collectively determine the company's success and valuation.

Direct, high-touch engagement with Key Opinion Leaders (KOLs) and oncologists

Oncolytics Biotech Inc. maintains direct engagement with Key Opinion Leaders (KOLs) to ensure clinical trial designs are relevant and to validate the science behind pelareorep. The company held a recent Key Opinion Leader event which reinforced the clinical promise of pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal (GI) cancers. If efficacy signals in indications like relapsed anal carcinoma persist in Stage 2 expansion cohorts, the company will engage with its scientific advisory board and KOLs to optimize development in that indication. This high-touch approach is standard for translating strong clinical data into accepted standards of care.

• Deloitte reports that more than 80% of pharma executives rely on external experts to shape clinical and commercial strategy in 2025.
• KOL involvement signals to regulatory authorities and Institutional Review Boards that research is clinically relevant and ethically sound.

Intensive regulatory dialogue with the U.S. FDA and other agencies

Regulatory alignment is a primary focus for Oncolytics Biotech Inc., especially for its Fast Track-designated programs in metastatic breast cancer and pancreatic cancer. The company confirmed active discussions with the U.S. Food and Drug Administration (FDA) to finalize parameters for a registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), with study start-up activities potentially commencing before the end of 2025. Specifically, the company was scheduled to meet with the FDA in mid-November 2025 to advance these study details. For the breast cancer program, a prior Type C meeting in June 2024 supported the planned potential registration-enabling trial, with the FDA supporting progression-free survival as the primary endpoint. Furthermore, Germany's Paul-Ehrlich-Institute (PEI) gave the go-ahead to fully enroll the GOBLET Cohort 5 study in pancreatic cancer following a positive safety review.

The planned pivotal trial for mPDAC is designed with three arms to establish regulatory rigor:

Arm Number	Treatment Regimen	Primary Endpoint Focus
1 (Control)	Gemcitabine + nab-paclitaxel (GnP)	Overall Survival (OS)
2 (Investigational)	GnP + pelareorep	Overall Survival (OS)
3 (Investigational)	GnP + pelareorep + checkpoint inhibitor (CPI)	Overall Survival (OS)

This design includes a planned interim efficacy analysis to enable early assessment of clinical benefit.

Investor relations focused on non-dilutive funding and shareholder value

Investor relations efforts are heavily concentrated on securing capital that minimizes shareholder dilution while funding key clinical milestones. Oncolytics Biotech Inc. has actively managed its financing structure through late 2025. The company reported cash and cash equivalents of $12.4 million as of September 30, 2025, which management indicated provides runway into the first quarter of 2026 without requiring additional funding. However, the Q3 2025 net loss was reported at $14.4 million, an increase from $9.5 million in the same period last year, underscoring the need for capital access. The company is a development-stage entity with no current revenue generation and an Earnings Per Share (EPS) of negative $0.27 trailing twelve months.

Here's a quick look at the capital structure and recent funding activities:

Financing Instrument/Metric	Amount/Value	Date/Period End
Cash & Cash Equivalents	$12.4 million	September 30, 2025
Q3 2025 Net Loss	$14.4 million	Three months ended September 30, 2025
Share Purchase Agreement (SPA) Maximum	Up to US$20 million	April 10, 2025 (over 15 months)
At-The-Market (ATM) Financing Maximum	Up to $50 million	Filed as of October 17, 2025
Total Institutional Investors	3	As of late 2025

The ATM financing with BTIG, LLC, offers a flexible means to secure capital at current market prices. The company's current market capitalization is approximately $109.33 million, with shares trading at $1.03 as of November 19, 2025.

Collaboration management with academic and advocacy groups (PanCAN)

Managing strategic collaborations is vital for advancing clinical proof points, particularly in complex indications like pancreatic cancer. Oncolytics Biotech Inc. has a key relationship with The Pancreatic Cancer Action Network (PanCAN). This relationship is formalized through a significant financial contribution supporting ongoing research. The GOBLET Cohort 5 study, which is evaluating pelareorep in newly diagnosed metastatic pancreatic cancer patients combined with modified FOLFIRINOX with or without atezolizumab, is directly supported by this partnership.

• GOBLET Cohort 5 for pancreatic cancer is funded by a $5 million grant from PanCAN.
• The company also has a collaboration with the Global Coalition for Adaptive Research (GCAR) to support pancreatic cancer research.
• Pelareorep has received Fast Track designation from the FDA for both metastatic breast and pancreatic cancers.

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Channels

The channels for Oncolytics Biotech Inc. (ONCY) are centered on clinical validation, regulatory engagement, and capital market communication to advance pelareorep.

Global network of clinical trial sites and academic research centers

The GOBLET study is currently being conducted at 17 centers in Germany for its Phase 1/2 indications. Oncolytics Biotech Inc. submitted a protocol amendment in September 2025 to open U.S. clinical sites for the GOBLET trial, with Northwestern University expected to serve as one of these locations. Enrollment for Cohort 4 in relapsed, unresectable SCAC indication is at 20 evaluable patients as of September 2025, with completion expected by the end of 2025.

Scientific conferences (ASCO GI, etc.) for data dissemination

Data dissemination channels include major medical meetings. Oncolytics Biotech Inc. presented data featuring pelareorep at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco from January 23-25, 2025. Further data from the GOBLET clinical trial was presented in a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025.

Direct communication with regulatory bodies (FDA, PEI)

Direct engagement with regulatory agencies is a critical channel for trial progression. Germany's Paul-Ehrlich-Institute (PEI) provided clearance for Oncolytics Biotech Inc. to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) following a safety review. The company initiated regulatory discussions with the U.S. Food and Drug Administration (FDA) for a potential registration-enabled pivotal study in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) in July 2025, expecting to commence study start-up activities before the end of 2025. By November 2025, Oncolytics Biotech Inc. announced alignment with the FDA on the pivotal study design.

Future licensing agreements with large pharmaceutical partners

The strategy involves advancing pelareorep through late-stage clinical testing to present the highest chance of success and greatest commercial opportunity, positioning the company for potential collaborations with industry leaders. The company is actively seeking strategic collaborations as part of its financing strategy.

Investor roadshows and SEC/SEDAR filings for capital markets

Investor communication channels include direct presentations and mandatory regulatory filings. CEO Jared Kelly presented at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9 and 10, 2025. The company filed a Form 6-K on October 10, 2025, submitting its corporate presentation to the SEC. For capital raising, Oncolytics Biotech Inc. launched an at-the-market offering of up to $50,000,000 in common shares, with the agent receiving a 3.0% commission. As of June 30, 2025, common shares outstanding were 97,407,903. The cash and cash equivalents balance as of September 30, 2025, was $12.4 million. The net loss for the period ending September 30, 2025, was $27.3 million.

Key Channel Metrics for Oncolytics Biotech Inc. as of Late 2025:

Channel Metric	Value/Amount	Date/Period Reference
GOBLET Trial Centers (Germany)	17	Q1-Q3 2025
U.S. Clinical Sites Planned	1+ (Including Northwestern University)	September 2025
SCAC Cohort 4 Enrollment (Target)	20 evaluable patients	Expected completion by end of 2025
At-The-Market Offering Size	Up to $50,000,000	October 2025 Filing
Agent Commission on Offering	3.0%	October 2025 Filing
Common Shares Outstanding	97,407,903	June 30, 2025
Cash and Cash Equivalents	$12.4 million	September 30, 2025
Net Loss Reported	$27.3 million	Period ending September 30, 2025

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Customer Segments

You're looking at the key groups Oncolytics Biotech Inc. (ONCY) targets for its pelareorep asset, which is a crucial part of understanding their path to commercialization and future valuation. Here are the concrete segments and the numbers we see as of late 2025.

Patients with hard-to-treat solid tumors, primarily mPDAC and mBC

This group represents the end-users who stand to benefit from pelareorep, which is designed to turn immunologically "cold" tumors "hot".

• The company is pursuing a potential registration-enabling trial in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
• In the BRACELET-1 study for metastatic breast cancer, the pelareorep + paclitaxel arm showed a 5.7-month PFS benefit over chemotherapy alone.
• In the IND-213 metastatic breast cancer study, median overall survival in the pela group was nearly double that in the control arm.
• For relapsed anal carcinoma (GOBLET Cohort 4), an interim objective response rate of 33% was reported, including one complete response lasting more than 15 months.
• GOBLET Cohort 5, targeting newly diagnosed metastatic pancreatic cancer, is set for Stage 1 enrollment with 30 patients across two treatment arms.
• The overall global oncology market was estimated at US$345.1 billion in 2025.

Large pharmaceutical and biotech companies seeking oncology assets

These are potential acquirers or partners, attracted by the clinical data and the clear regulatory path Oncolytics Biotech Inc. is establishing. The team's pedigree is relevant here; the CEO and CBO were involved in Ambrx Biopharma's US$2 billion acquisition by Johnson & Johnson.

Oncolytics Biotech Inc. has secured flexible financing options, signaling a need to bridge to key milestones before a potential partnership or acquisition. They have:

• An at-the-market (ATM) equity financing agreement with BTIG, LLC to sell up to $50 million in common stock.
• A Share Purchase Agreement (SPA) with Alumni Capital LP to sell up to US$20 million worth of stock over a 15-month period.
• Management acknowledges the need for additional financing to sustain operations beyond March 2026.

Institutional investors and specialist biotech funds (e.g., Alumni Capital)

This segment is focused on the capital structure and ownership base. As of the latest filings, the institutional picture looks like this:

Metric	Value as of Late 2025
Total Institutional Owners (13F/G Filers)	59
Total Institutional Shares Held (Long)	2,887,189
Institutional Ownership Percentage	6.82%
Share Price (as of Dec 2, 2025)	$0.88 / share
Market Capitalization (Approx.)	$119.47 million
Total Shares Outstanding (Millions)	106

Key named investors include Alumni Capital, which entered via an SPA on April 10, 2025. Other major holders as of September 30, 2025, show significant positions:

• Morgan Stanley: 383,346 shares
• Citadel Advisors Llc: 382,051 shares
• Marshall Wace, Llp: 323,982 shares

Honestly, the low institutional ownership percentage of 6.82% suggests significant room for institutional accumulation as clinical milestones are hit.

Academic and cooperative oncology groups (e.g., GCAR)

These groups provide critical validation, trial infrastructure, and often, non-dilutive funding, which is key for a clinical-stage company. Oncolytics Biotech Inc. has formalized relationships here:

• The company established a collaboration with the Global Coalition for Adaptive Research (GCAR) for the pancreatic cancer program.
• The GOBLET Cohort 5 study is supported by a $5 million grant from the Pancreatic Cancer Action Network (PanCAN).
• Oncolytics established a Gastrointestinal Tumor Scientific Advisory Board on November 4, 2025.

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Oncolytics Biotech Inc. (ONCY) as they push pelareorep through late-stage clinical development. For a clinical-stage biopharma, the cost structure is almost entirely driven by R&D, which is where the bulk of the cash burn happens. Honestly, this is the engine room of the business model right now.

The primary cost drivers are Research and Development (R&D) expenses, which cover everything from running the trials to the actual production of the drug substance. General and Administrative (G&A) costs are the next big bucket, covering the corporate overhead needed to keep the lights on and the SEC filings current.

Here's the quick math on the first quarter of 2025 expenditures, based on their reported figures:

• Research and Development (R&D) expenses, including clinical trial costs: totaled $4.1 million.
• General and Administrative (G&A) expenses, including personnel and legal fees: totaled $3.0 million.

To give you a clearer picture of where that R&D dollar went in Q1 2025, we can look at the components, which are reported in thousands of Canadian dollars (CAD). This level of detail helps map the spend against clinical milestones.

R&D Component (Q1 2025)	Amount (in thousands of CAD)	Change from Q1 2024 (in thousands of CAD)
Clinical trial expenses	$516	($286)
Manufacturing and related process development expenses	$578	($2,600)
Intellectual property expenses	$149	$23

Notice the significant drop in manufacturing and related process development costs year-over-year for Q1 2025, down by $2,600 thousand CAD, which suggests a shift in the manufacturing schedule or a transition to a different phase of production for pelareorep. Still, manufacturing costs for the pelareorep drug substance and product remain a key component of the overall R&D spend.

General and Administrative (G&A) expenses are the second major category. These costs are primarily public company-related expenses, office costs, share-based compensation, and legal/accounting fees. For Q1 2025, the G&A spend was $3.0 million. This figure was noted as consistent with the prior year, which is a good sign of cost control in overhead, even as the company progresses its pipeline.

Looking at the subsequent quarter, Q2 2025, the cost structure showed some movement, which is important for your near-term cash view. R&D expenses decreased to $2.8 million CAD, primarily due to lower clinical trial expenses as the focus narrowed to Cohort 5 of the GOBLET study, which is supported by the Pancreatic Cancer Action Network award. G&A expenses for Q2 2025 were $2.9 million CAD, down from $3.4 million CAD in Q2 2024, mainly due to lower public company-related expenses, though personnel costs partially offset this reduction.

The total cash used in operating activities for the first six months of 2025 was $12.0 million CAD. This reflects the ongoing investment required to support the clinical programs for pelareorep.

Here is a summary of the key expense figures we have for the first half of 2025, using the most recent data points available:

• Q1 2025 R&D Expenses: $4.1 million (Source 1)
• Q1 2025 G&A Expenses: $3.0 million (Source 1)
• Q2 2025 R&D Expenses: $2.8 million CAD (Source 6)
• Q2 2025 G&A Expenses: $2.9 million CAD (Source 6)
• Net Cash Used in Operating Activities (6 months ended June 30, 2025): $12.0 million CAD (Source 6)

Finance: draft 13-week cash view by Friday.

Oncolytics Biotech Inc. (ONCY) - Canvas Business Model: Revenue Streams

You're looking at the current financial reality for Oncolytics Biotech Inc. (ONCY) as of late 2025. Honestly, for a clinical-stage company like this, the revenue stream block in the Business Model Canvas is almost entirely populated by non-operating capital sources right now, which is typical for the sector.

Currently pre-commercial with $0.00 actual revenue reported in Q3 2025

Oncolytics Biotech Inc. (ONCY) is operating in a pre-commercial phase, meaning product sales are not yet a source of income. The financial results for the third quarter ended September 30, 2025, reflect this, showing a net loss of $14.4 million for the quarter. Furthermore, the company reported an Earnings Per Share (EPS) of -$0.10 for Q3 2025. The trailing twelve months ending September 30, 2025, showed earnings of -$25.2 million. This lack of operating revenue is supported by statements indicating no current revenue generation.

Non-dilutive funding from grants

A key non-dilutive inflow has been grant funding, specifically the award from the Pancreatic Cancer Action Network (PanCAN). Oncolytics Biotech Inc. was selected to receive a $5 million Therapeutic Accelerator Award from PanCAN. This $5 million grant is earmarked to support the next stage of research, including a Phase 2 study arm evaluating pelareorep in combination with modified FOLFIRINOX chemotherapy.

Equity financing through ATM and Share Purchase Agreements

To bridge the gap until potential commercialization, Oncolytics Biotech Inc. has secured access to capital through equity financing mechanisms. Most recently, as of October 2025, Oncolytics Biotech Inc. entered into a new at-the-market (ATM) equity financing agreement allowing the company to sell up to $50 million in common stock. This deal, managed by BTIG, LLC, provides a flexible means to secure capital for operations and research efforts by selling shares directly on the market at prevailing prices. This is a significant facility, similar to a previous $50 million USD ATM offering launched in August 2024.

Here's a quick look at the capital sources supporting operations as of late 2025:

Revenue/Funding Stream Type	Specific Source/Program	Reported Amount/Status (Late 2025)
Actual Operating Revenue	Product Sales	$0.00 (Pre-commercial)
Non-Dilutive Funding (Grant)	PanCAN Therapeutic Accelerator Award	$5 million
Equity Financing (ATM Facility)	Agreement with BTIG, LLC (as of Oct 2025)	Up to $50 million available
Operating Performance (Loss)	Q3 2025 Net Loss	$14.4 million

Future potential revenue from upfront payments and milestones from licensing deals

The primary long-term revenue potential for Oncolytics Biotech Inc. lies in successful commercialization, which is often preceded by strategic partnerships. The company is actively advancing discussions to secure these deals. Future revenue streams are structured to include:

• Upfront payments received upon signing a licensing or collaboration agreement.
• Milestone payments triggered by achieving specific clinical or regulatory success points.

Future product sales royalties or direct sales post-approval

Once a therapeutic candidate, like pelareorep, achieves regulatory approval in key markets, the revenue model shifts to commercial realization. This is the ultimate goal for the company's value creation. This future stream is anticipated to come from:

• Royalty payments based on net sales generated by a commercial partner.
• Direct sales revenue if Oncolytics Biotech Inc. chooses to retain or build out its own commercial infrastructure in certain territories post-approval.

Finance: draft 13-week cash view by Friday.